Comparative Pharmacology
Head-to-head clinical analysis: BRIVIACT versus EXTENDED PHENYTOIN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRIVIACT versus EXTENDED PHENYTOIN SODIUM.
BRIVIACT vs EXTENDED PHENYTOIN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Brivaracetam is a synaptic vesicle glycoprotein 2A (SV2A) ligand with high affinity. The exact mechanism by which it exerts its antiepileptic effect is unknown, but binding to SV2A is thought to modulate neurotransmitter release.
Phenytoin stabilizes neuronal membranes by promoting sodium channel inactivation, reducing repetitive firing of action potentials, and decreasing synaptic transmission.
50 mg orally twice daily; may increase up to 100 mg twice daily based on response and tolerability.
Oral: 100 mg three times daily; intravenous: 10-20 mg/kg loading dose at a maximum rate of 50 mg/min, then 100 mg every 6-8 hours maintenance.
None Documented
None Documented
Terminal elimination half-life is approximately 9 hours (range 7–11 hours). This supports a twice-daily dosing regimen (e.g., 50 mg twice daily) with steady state achieved within approximately 2 days.
22–32 hours (mean 24 hours) in adults, dose-dependent due to saturable metabolism; may exceed 60 hours at high concentrations.
Approximately 95% of the dose is excreted in urine as metabolites or unchanged drug (<1% unchanged). About 0.8% is excreted in feces via biliary elimination.
Primarily hepatic metabolism (CYP2C9/CYP2C19), with <5% excreted unchanged renally. Fecal excretion accounts for minor elimination.
Category C
Category D/X
Anticonvulsant
Anticonvulsant